A History of Outperforming Analyst Forecasts and Beating the Odds: Avadel Pharmaceuticals plc (AVDL)

With 1.25 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.42 million shares. The 52-week range on AVDL shows that it touched its highest point at $19.09 and its lowest point at $7.39 during that stretch. It currently has a 1-year price target of $18.00. Beta for the stock currently stands at 1.55.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AVDL was up-trending over the past week, with a rise of 0.79%, but this was down by -4.87% over a month. Three-month performance dropped to -23.59% while six-month performance fell -47.97%. The stock lost -53.37% in the past year, while it has lost -27.59% so far this year. A look at the trailing 12-month EPS for AVDL yields -0.52 with Next year EPS estimates of 0.65. For the next quarter, that number is -0.06. This implies an EPS growth rate of 125.29% for this year and 406.50% for next year.

Float and Shares Shorts:

At present, 96.52 million AVDL shares are outstanding with a float of 88.35 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AVDL since 8 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.45185 being high and -$0.53043 being low. For AVDL, this leads to a yearly average estimate of -$0.50096. Based on analyst estimates, the high estimate for the next quarter is $0.02 and the low estimate is -$0.04. The average estimate for the next quarter is thus $0.0.